About this trial
Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the interventional arm which has the additional use of MRI imaging and subsequent discussion by the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL questionnaires.
Eligibility criteria
Qualifiers
Have a suspected or proven sigmoid colon adenocarcinoma
Is eligible for curative treatment
Has no irresectable metastatic disease
MRI can be reviewed by an MDT prior to surgery
Disqualifiers
Have metastatic disease (including resectable liver metastases)
Have a synchronous second malignancy
Are contraindicated for MRI
Are contraindicated for or have allergy to Buscopan (e.g. glaucoma, small or large bowel obstruction, GFR<30)
Trial design
Treatments tested in this trial
- Preoperative MRI scan
Treatment groups
Sponsors and collaborators
Imperial College London
Lead sponsor
Pelican Cancer Foundation
Collaborator